These findings suggest that PTPN11 mutation may induce LS beyond the mTORC1 pathway, while primary hyperactivation of mTORC1 is not a prerequisite for the hypertrophy-reversing effect of rapamycin. The gene discussed is PTPN11; the disease is Leigh syndrome.